Abstract
BackgroundTo evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with nocturnal bruxism.Material and MethodsFifty subjects reporting nocturnal bruxism were recruited for a randomized clinical trial. Twenty five bruxers were injected with botulinum toxin in both masseters, and twenty five were treated with traditional methods of treating bruxism. Patients were evaluated at 3rd week, 2nd and 6th month and one year after injection and then used to calculate bruxism events. Bruxism symptoms were investigated using questionnaires.ResultsMean pain score due to Bruxism events in the masseter muscle decreased significantly in the botulinum toxin injection group A (P =0.000, highly significant). However, in the conventional treatment group, mean pain score does not show improvement with time (p>0.05).ConclusionsOur results suggest that botulinum toxin injection reduced the mean pain score and number of bruxism events, most likely by decreasing the muscle activity of masseter rather than affecting the central nervous system. Key words:Temporomandibular pain, nocturnal bruxism, botulinum toxin.
Highlights
Bruxism, which includes clenching or grinding of the teeth, or both, affects from 50% to 95% of the adult population [1,2,3]
The aim of the present study is to evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with nocturnal bruxism when compared to traditional methods of treatment
There was no significant difference in mean pain score pre-operatively in group I and group II
Summary
Bruxism, which includes clenching or grinding of the teeth, or both, affects from 50% to 95% of the adult population [1,2,3]. Various forms of bruxism have been described [4,5] The etiology of this disorder is uncertain. Several experts have suggested that bruxism may itself be a form of focal dystonia [9]. To evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with nocturnal bruxism. Twenty five bruxers were injected with botulinum toxin in both masseters, and twenty five were treated with traditional methods of treating bruxism. Results: Mean pain score due to Bruxism events in the masseter muscle decreased significantly in the botulinum toxin injection group A (P =0.000, highly significant). Conclusions: Our results suggest that botulinum toxin injection reduced the mean pain score and number of bruxism events, most likely by decreasing the muscle activity of masseter rather than affecting the central nervous system
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
